EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases

Scott R Anderson iD, Ali Osman iD, Mohammad Zamani, Quazim Alayo, Andres J Yarur, Deborah Thomas, Suzannah Bergstein, Elizabeth Spencer, Bruce E Sands, Jean-Francois Rahier, Jean-Frederic Colombel, Parakkal Deepak iD

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izaf188 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Scott R Anderson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States. Hauptthemen laut MEDLINE: Biological Products, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The systematic review and meta-analysis (SRMA) evaluates the safety and effectiveness of combining biologics and/or small molecules in treating refractory inflammatory bowel diseases (IBD).

Methods

Our 2022 SRMA identified 13 studies published until November 3, 2020. An updated systematic search was completed from May 2020 through January 31, 2024. Random-effects inverse variance model was used to calculate pooled estimates for adverse events (AEs) and clinical and endoscopic-radiologic response/remission rates in IBD patients.

Results

Twenty-seven eligible studies had 619 patients and 631 therapeutic trials (TTs). Upadacitinib (UPA) + vedolizumab (VDZ) and tofacitinib (Tofa) + anti-TNF (aTNF) had the lowest AEs rate (0%, 2 TTs) and (9.2%, 33 TTs), respectively. Higher AE rates were seen in natalizumab (NAT) + aTNF (92.3%, 52 TTs) and aTNF + guselkumab (63.4%, 71 TTs). No serious AEs (SAEs) were observed in NAT + aTNF (52 TTs), Tofa + ustekinumab (UST) (23 TTs), and UPA + VDZ (2 TTs). The highest rate of SAEs was observed in UPA + UST (23%, 17 TTs). UPA + UST and UPA + VDZ had 100% clinical response rates and the highest clinical remission rates (83.3%, 12 TTs) and (100%, 2 TTs), respectively. High clinical response rates were also seen in Tofa + aTNF (82.7%, 34 TTs), UST + aTNF (82.1%, 63 TTs), and VDZ + UST (82.0%, 71 TTs).

Conclusions

Combining biologics and/or small molecules may be effective for IBD patients who fail to achieve remission with monotherapy; however, safety profiles need to be carefully considered prior to implementing these strategies in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsInflammatory Bowel DiseasesGastrointestinal AgentsHumansDrug Therapy, CombinationAntibodies, Monoclonal, HumanizedPiperidinesHeterocyclic Compounds, 3-RingTreatment OutcomePyrimidines

Substanzen

Biological ProductsvedolizumabtofacitinibAntibodies, Monoclonal, HumanizedGastrointestinal AgentsPiperidinesHeterocyclic Compounds, 3-RingupadacitinibPyrimidines

Autor:innen und Institutionen

  • Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States.
  • Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, United States.
  • Bernard Becker Medical Library, Washington University in St. Louis, St. Louis, Missouri, United States.
  • Division of Pediatric Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
  • Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States.

ORCID-Profile: Scott R Anderson, Ali Osman, Parakkal Deepak

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Anderson, S. R., Osman, A., Zamani, M., Alayo, Q., Yarur, A. J., Thomas, D., Bergstein, S., Spencer, E., Sands, B. E., Rahier, J. F., Colombel, J. F., & Deepak, P. (2026). Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf188

Vancouver

Anderson SR, Osman A, Zamani M, Alayo Q, Yarur AJ, Thomas D, et al. Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf188

BibTeX
@article{Anderson2026,
  author = {Anderson, Scott R and Osman, Ali and Zamani, Mohammad and Alayo, Quazim and Yarur, Andres J and Thomas, Deborah and Bergstein, Suzannah and Spencer, Elizabeth and Sands, Bruce E and Rahier, Jean-Francois and Colombel, Jean-Frederic and Deepak, Parakkal},
  title = {Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izaf188}
}
Kostenlos starten →